Angiotensin receptor antagonists have demonstrated beneficial effects on hard clinical endpoints in patients with hypertension, heart failure, diabetic nephropathy, and post-myocardial infarction.
This review summarizes the historical and clinical evidence supporting the use of angiotensin receptor antagonists across various cardiovascular and renal diseases.
More than a century of research on the reninangiotensin system (RAS) has uncovered the widespread involvement of angiotensin II (Ang II) in the pathophysiology of cardiovascular diseases. A number of outcomes-based mega trials utilising hard clinical endpoints have revealed beneficial effects of angiotensin receptor antagonists (AIIAs/ARBs) in patients with hypertension, heart failure, diabetic nephropathy, and post-myocardial infarction (MI). The results of these studies not only emphasise the importance of Ang II in the pathophysiology of these diseases but have provided the basis for an evidence-based approach for the use of AIIAs in clinical practice. It is hoped that the next 100 years of research into the RAS will uncover hitherto unimaginable therapeutic opportunities.
Carlos M. Ferrario (2006) conducted a review in Cardiovascular diseases (hypertension, heart failure, diabetic nephropathy, post-myocardial infarction). Angiotensin receptor antagonists (AIIAs/ARBs) was evaluated. Angiotensin receptor antagonists have demonstrated beneficial effects on hard clinical endpoints in patients with hypertension, heart failure, diabetic nephropathy, and post-myocardial infarction.